ArticleBladder (San Francisco, Calif.)2025
Accuracy and limitations of ureteroscopic biopsy in the staging and grading of upper tract urothelial carcinoma: A retrospective analysis at a large tertiary center.
Article in Bladder (San Francisco, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Imaging in Upper Tract Urothelial Carcinoma: Diagnostic Accuracy of Current Modalities for Local Tumor Staging.Current urology reports · 2026Review
- Noninvasive differentiation of upper tract urothelial carcinoma and renal cell carcinoma in challenging renal lesions using urinary DNA methylation.BJUI compass · 2026Article
- Impact of body mass index on outcomes after radical cystectomy: A retrospective Australian cohort study.BJUI compass · 2026Article
- Validation of the diagnostic accuracy of a urine-based DNA methylation marker test in patients with upper urinary tract lesions.BJUI compass · 2026Article
- Beyond conventional forceps: suction biopsy and cryobiopsy in upper tract urothelial tumors.Central European journal of urology · 2026Article
- Machine learning-based integration of systemic immune-inflammation and nutritional signatures for predicting disease-free survival in upper tract urothelial carcinoma: a multicenter study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Upper tract urothelial carcinoma (UTUC) poses significant diagnostic challenges due to the limitations of current staging and grading techniques. Ureteroscopic (URS) biopsy is widely used preoperatively, but its accuracy, compared to final pathology, remains variable. Objectives: To evaluate the accuracy and limitations of URS biopsy in the staging and grading of UTUC, using final pathological results from radical nephroureterectomy (RNU) as the reference standard. Methods: This retrospective study included 86 patients who underwent URS biopsy followed by RNU for UTUC at a tertiary institution between 2011 and 2023. Data were collected on patient demographics, tumor characteristics, imaging, and pathology results. The accuracy of URS biopsy in staging and grading was assessed, and its associations with pathological upstaging and non-diagnostic biopsies were statistically analyzed. Results: URS biopsy correctly staged 54.69% of tumors (κ = 0.311 [0.183 - 0.439], p<0.001) and correctly graded 70.93%. (κ = 0.447 [0.303 - 0.592], p<0.001). Pathological upstaging and upgrading occurred in 39.06% and 25.58% of cases, respectively. Non-diagnostic biopsies for both stage and grade were observed in 5.81% of cases, particularly in tumors located in the renal pelvis (p=0.0064). Complementary diagnostic tools, such as computed tomography urography (CTU) and urine cytology, showed limitations, with CTU detecting invasive disease in only 14.29% of cases and urine cytology identifying high-grade tumors in 11.11%. Conclusion: URS biopsy demonstrates limitations in accurately staging and grading UTUC, resulting in a risk of both undertreatment and overtreatment. A multimodal diagnostic approach incorporating imaging, cytology, and clinical judgment is essential to optimizing management decisions and improving oncological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.